North County Neurology Associates/The Research Center of Southern California, LLC
6010 Hidden Valley Road, Suite 200
Carlsbad, CA 92011
Phone: 760-631-3000
Fax: 760-631-3016

John Peter Heinen, PA-C

EDUCATION

San Diego State University, San Diego, California ■ 08/1973 - 05/1975
B.S. Degree in Zoology

Baylor College of Medicine, Houston, Texas ■ 06/1975 – 09/1977
B.S. Degree in Health Science and PA certificate

LICENSURE

Certified Physician Assistant License # PA 10565 ■ Current
DEA License #MH0594641 ■ Current
American Heart Association – ACLS & BLS ■ Current

CERTIFICATION

National Commission on Certification of Physician Assistants # 1004806 ■ 07/1979- Present

PROFESSIONAL EXPERIENCE

Physician Assistant Certified, The Neurology Center of Southern California, Carlsbad, CA
■ 09**/**2007- Present

Sub-Investigator, North County Neurology Associates/The Research Center of Southern California, Carlsbad, CA ■ 01/2007- Present

Physician Assistant, Pacific Pain Medicine Consultants, Encinitas, California ■ 09/2002 - 09/2007

Physician Assistant, Navcare Prime Clinic, San Diego, California ■ 06/1997 – 09/2002

Physician Assistant, Women's Healthcare Center, National City, California ■ 04/1996 – 05/1997

Physician Assistant, Joseph S. Freitas, M.D. Clinic, National City, California ■ 03/1982 – 04/1996
(No longer in **business)**

Physician Assistant, John R Ford M.D., Inc., San Diego, California ■ 07/1977 – 03/1982
(No longer in business)

E-5 Hospital Corpsman-Operating Room Technician, Unites States Navy ■ 1968-1972

Honorable Discharge ■ 1973

HOSPITAL AFFILIATIONS

Scripps Memorial Hospital, Encinitas, California	■ 03/2003 – Present
Tri-City Medical Center, Oceanside, California	■ 01/2020 - Present

PROFESSIONAL SOCIETIES

American Academy of Physician Assistants	■ Current Member
California Academy of Physician Assistants	■ Current Member

RESEARCH ACTIVITIES

Alzheimer's disease

ELN115727-301 & 302 "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trail of Bapineuzumab (AAB-001,ELN115727 in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein E ε4 Non- Carriers (301) or Carriers (302). Sub-Investigator - 2008

ELN115727-351"A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001,ELN115727)in Subjects with Alzheimer's Disease who Participated in Study ELN115727-301 or in Study ELN115727-302" Sub-Investigator - 2009

AAB-001-SC-ALZ-2003: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects with Mild to Moderate Alzheimer's disease. Sub-Investigator – 2010

251AD201: Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer's disease or with Mild Alzheimer's Disease. Sub-Investigator – 2017

I5T-MC-AACI. Assessment of safety, tolerability, and efficacy of Donanemab in early symptomatic Alzheimer's disease. Sub-Investigator– 2020

Migraine

ALD403-CLIN-011 A Parallel Group Double Blind Randomized Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine. Sub-Investigator – 2016

Migraine *Continued*

A Parallel Group Double Blind Randomized Placebo- Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine. Protocol Number: ALD403-CLIN-015. Sub-Investigator – 2019

Multiple Sclerosis

CFTY720D2309: A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis with optional extension phase Protocol No.: CFTY720D2309. Sub-Investigator - 2007

Extension to CFTY720D2309 (A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5mg and 1.25mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. Sub-Investigator - 2007

CFTY720D2302: A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon β-1a (Avonex®) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase. Sub-Investigator - 2007

FTY Prefer: A 12-month, Prospective, Randomized, active-controlled, open label study to evaluate the patient retention of Fingolimod vs. approved first- line disease modifying therapies in adults who are in early stages of treatment for Relapsing Remitting Multiple Sclerosis. Sub-Investigator - 2012

Novartis Assess FTY (2312): Fingolimod vs. Glatiramer Acetate A 12-month, randomized, rater and dose-blinded study to compare the efficacy and safety of fingolimod 0.25mg and .05mg administered orally once daily with glatiramer acetate 20mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis. Sub-Investigator - 2013

CFTY20D2399: A single arm, open label, multicenter study evaluating the long-term safety and tolerability of 0.5mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis. Sub-Investigator - 2013

CBAF312A2304: A multicenter, randomized, double blind, parallel group, placebo controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis. Sub-Investigator - 2014

CHORDS: MN30035- An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Relapsing Remitting multiple Sclerosis Who Have Had a Suboptimal Response To An Adequate Course Of Disease-Modifying Treatment. Sub-Investigator - 2016

TG1101-RMS30: Phase III: UbLiTuximab In Mutliple Sclerosis Treatment Effects (ULTIMATE I Study) Sub-Investigator - 2017

ABBVIE M14-397: MS Safety and Efficacy study of Elezanumab (ABT-555) in Progressive Forms of MS. Sub-Investigator - 2018

ABBVIE M18-918: MS Safety and Efficacy study of Elezanumab (ABT-555) in Relapsing Forms of MS. Sub-Investigator – 2018

BN42082: A phase IIIB multicenter, randomized double blind, controlled study to evaluate the efficacy, safety and pharmacokinetics of a higher dose of Ocrelizumab in adults with relapsing multiple sclerosis. Sub-Investigator - 2020

GN41851. A phase III multicenter, randomized, double blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Fenebrutinib compared with Teriflunomide in adult patients with relapsing Multiple Sclerosis. Sub-Investigator - 2020

Myasthenia Gravis

ARGX-113-1704. A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle Weakness. Sub-Investigator – 2019

ARGX-113-1705. A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Muscle Weakness. Sub-Investigator – 2020

Parkinson's disease

S187.3.002: A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments with Parkinson Medicinal Products, who Continue to Experience Persistent Motor Fluctuations. Sub-Investigator - 2010

S187.3.003: Open-Label, 12-Month Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects. Sub-Investigator - 2010

S187.3.004: An Open-Label, 12 Month Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations Despite Optimized Treatment with Available Parkinson's Disease Medications. Sub-Investigator - 2010

S187.3.005: Open-Label Contiuation Treatment Study With Levodopa-Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuation Who Have Exhibited A Persistent And Positive Effect To Treatment in Previous Studies. Sub-Investigator - 2010

M12-920: An Open-Label, Two Part, Multi-Center Study to Assess the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease. Sub-Investigator – 2014

A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson's disease experiencing motor fluctuations (BouNDless) ND0612-317. Sub-Investigator - 2020

Other

Alexion ECU-NMO-301: A Randomized, Double Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients with Relapsing Neuromyelitis Optica. Sub-Investigator – 2014

Alexion ECU-NMO-302: A Phase III, Open-Label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients with Relapsing Neuromyelitis Optica. Sub-Investigator - 2014

ALXN-1210-NMO-307: A phase 3, external placebo-controlled, open label, multicenter study to evaluate the efficacy and safety of Ravulizumab in adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) Sub-Investigator- 2020